Thank you very much, Mr. Chairman.
As Madam Gosselin said, we have followed up on the recommendations of the Auditor General and of this committee. We have put in place a drug utilization review regime that had three components. There is a prospective component that controls the formula in the drugs that we pay for, and we've done a number of things. We've identified those drugs that are at risk and we've taken them off our formulary or put them onto an area where you cannot get them except with special permission from your physician. We've put limits on the number of drugs, on the drugs like benzodiazepine and opiates, so that when people use over a certain limit, they are cut off and they can't get any more until their physician approaches us or their pharmacist explains why.
We've also put in place a new code, an NE code. At the time that the pharmacist is filling out a prescription, it will identify whether or not that patient has had a multiple benzodiazepine or opiate-type pharmacy. The pharmacist will get a notice right then and there that there may be a problem.
We've also implemented a retrospective review. We do it six times a year. We take the records that we have and we have a system that identifies whether people have been to a number of doctors, whether they are receiving a number of medications. We identify those individuals and we follow up with those individuals. We have identified individual physicians where we have problems. We have gone through the Federation of Medical Regulatory Authorities and taken our evidence there. We've gone to the individual--